KR101723435B1 - Novel human gene crucial for the replication of influenza virus and use thereof - Google Patents
Novel human gene crucial for the replication of influenza virus and use thereof Download PDFInfo
- Publication number
- KR101723435B1 KR101723435B1 KR1020160077941A KR20160077941A KR101723435B1 KR 101723435 B1 KR101723435 B1 KR 101723435B1 KR 1020160077941 A KR1020160077941 A KR 1020160077941A KR 20160077941 A KR20160077941 A KR 20160077941A KR 101723435 B1 KR101723435 B1 KR 101723435B1
- Authority
- KR
- South Korea
- Prior art keywords
- ddx19b
- gene
- influenza virus
- protein
- sirna
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 88
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 69
- 230000010076 replication Effects 0.000 title claims abstract description 22
- 101150041494 DDX19B gene Proteins 0.000 claims abstract description 67
- 101000830477 Homo sapiens ATP-dependent RNA helicase DDX19B Proteins 0.000 claims abstract description 44
- 102100024736 ATP-dependent RNA helicase DDX19B Human genes 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 230000014509 gene expression Effects 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000003112 inhibitor Substances 0.000 claims abstract description 26
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 24
- 238000012216 screening Methods 0.000 claims abstract description 22
- 239000003443 antiviral agent Substances 0.000 claims abstract description 21
- 230000009385 viral infection Effects 0.000 claims abstract description 21
- 108020004459 Small interfering RNA Proteins 0.000 claims description 55
- 239000004055 small Interfering RNA Substances 0.000 claims description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 238000003757 reverse transcription PCR Methods 0.000 claims description 11
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 241000252870 H3N2 subtype Species 0.000 claims description 5
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 5
- 230000002860 competitive effect Effects 0.000 claims description 5
- 239000002679 microRNA Substances 0.000 claims description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 4
- 108700011259 MicroRNAs Proteins 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims description 4
- 102100034343 Integrase Human genes 0.000 claims description 3
- 238000000636 Northern blotting Methods 0.000 claims description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 3
- 102000006382 Ribonucleases Human genes 0.000 claims description 3
- 108010083644 Ribonucleases Proteins 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 abstract description 17
- 230000004913 activation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 24
- 239000005090 green fluorescent protein Substances 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 241000700605 Viruses Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- 101000972846 Homo sapiens Glutamate receptor ionotropic, NMDA 2C Proteins 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 11
- 101001001294 Homo sapiens Lysosomal acid phosphatase Proteins 0.000 description 11
- 102100035699 Lysosomal acid phosphatase Human genes 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 101000708874 Homo sapiens Zinc finger protein ubi-d4 Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 230000004952 protein activity Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 241000712431 Influenza A virus Species 0.000 description 8
- 108010015268 Integration Host Factors Proteins 0.000 description 8
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
- 102100032701 Zinc finger protein ubi-d4 Human genes 0.000 description 8
- 230000009368 gene silencing by RNA Effects 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 101710144127 Non-structural protein 1 Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 241000856131 recombinant Influenza A viruses Species 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- 241000713196 Influenza B virus Species 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- -1 pH adjusters Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010091675 Cellular Apoptosis Susceptibility Protein Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100029091 Exportin-2 Human genes 0.000 description 2
- 229940122498 Gene expression inhibitor Drugs 0.000 description 2
- 101100485290 Homo sapiens CSE1L gene Proteins 0.000 description 2
- 101710128560 Initiator protein NS1 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000197306 H1N1 subtype Species 0.000 description 1
- 241001676764 H7N4 subtype Species 0.000 description 1
- 241000252868 H7N7 subtype Species 0.000 description 1
- 101100524349 Homo sapiens DPF2 gene Proteins 0.000 description 1
- 101000597417 Homo sapiens Nuclear RNA export factor 1 Proteins 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101150076514 NS gene Proteins 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108050000506 Nuclear RNA export factor Proteins 0.000 description 1
- 102000008731 Nuclear RNA export factor Human genes 0.000 description 1
- 102100035402 Nuclear RNA export factor 1 Human genes 0.000 description 1
- 101710139195 Nuclear RNA export factor 1 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010049219 RNA-dependent ATPase Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 102000046165 human NXF1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Description
The present invention relates to a novel human gene involved in the replication of influenza virus and its use. More specifically, the present invention includes an inhibitor of expression of DDX19B gene, an inhibitor of DDX19B protein activity, or a mixture thereof, which is involved in replication of influenza virus A method for screening an antiviral agent against influenza virus and a method for screening an antiviral agent by measuring the level of the mRNA of the DDX19B gene or a protein of the DDX19B gene in a pharmaceutical composition for preventing or treating influenza virus infection .
Influenza drugs currently target only two proteins, the M2 ion channel and neuraminidase, both of which are viral gene products. Unfortunately, at present, resistance to both types of drugs is widespread, and there is an urgent need for novel antiviral drugs for the prevention of pandemic influenza and pandemic influenza worldwide. Host factors that regulate viral replication during infection have been considered attractive antiviral targets because they have distinctive features that lack the high mutation rate of influenza virus genes that enable the development of resistance to current drugs.
On the other hand, DDX19B (DEAD box polypeptide 19B) is a type II transmembrane serine (II) transmembrane serine protease showing a complex molecular structure characterized by the presence of three tandem serine protease domains in its amino acid sequence protease). Although this protease is widely expressed in mouse and human tissues, its functional significance is unknown in both normal and pathological conditions.
Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication (Nature 463: 818-822, 2010) by Karlas A, et al., And presents various genes including GRIN2C gene as an important host factor for influenza virus replication However, there is no mention of the fact that the DDX19B gene plays an important role in the influenza virus.
Under these circumstances, the present inventors have made intensive efforts to search for a new target for developing an antiviral agent against influenza virus. As a result, the human DDX19B gene acts as an important host factor required for replication of influenza virus, Or activity of the influenza virus is effective in preventing or treating influenza virus infection, the present invention has been completed.
It is an object of the present invention to provide a pharmaceutical composition for preventing or treating an influenza virus infection comprising an inhibitor of expression of DDX19B (DEAD box polypeptide 19B) gene, an inhibitor of DDX19B protein activity or a mixture thereof as an active ingredient.
Another object of the present invention is to provide a health functional food for preventing or ameliorating an influenza virus infection comprising an inhibitor of expression of DDX19B (DEAD box polypeptide 19B) gene, an inhibitor of DDX19B protein activity or a mixture thereof as an active ingredient.
Yet another object of the present invention is to provide a method for detecting a DDX19B gene, comprising the steps of: (a) treating a candidate sample for antiviral treatment with a separate sample expressing the DDX19B gene and measuring the level of the mRNA or the protein thereof; And (b) selecting as an antiviral agent against influenza virus when the level of the mRNA of the gene or the protein thereof is lower than that of the control sample not treated with the candidate substance. will be.
It is still another object of the present invention to provide a screening kit for anti-viral agents against influenza virus comprising an agent for measuring mRNA of DDX19B gene or a protein level thereof.
In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating an influenza virus infection comprising an inhibitor of expression of DDX19B (DEAD box polypeptide 19B) gene, an inhibitor of DDX19B protein activity or a mixture thereof as an active ingredient do.
According to a preferred embodiment of the present invention, the influenza virus may be influenza A virus.
According to a preferred embodiment of the present invention, the DDX19B gene may be involved in replication of an influenza virus.
According to another preferred embodiment of the present invention, the DDX19B gene expression inhibitor may be selected from the group consisting of antisense, oligonucleotide, siRNA, shRNA and microRNA of DDX19B gene.
According to another preferred embodiment of the present invention, the siRNA may be any one selected from the group consisting of SEQ ID NOS: 1 to 4.
According to another preferred embodiment of the present invention, the activity inhibitor may be an antibody or an aptamer which specifically binds to DDX19B protein.
The present invention also provides a health functional food for preventing or ameliorating an influenza virus infection comprising an inhibitor of expression of DDX19B (DEAD box polypeptide 19B) gene, an inhibitor of DDX19B protein activity, or a mixture thereof as an active ingredient.
The present invention also provides a method for screening a DDX19B gene, comprising the steps of: (a) treating an antiviral candidate substance to a separated sample expressing the DDX19B gene, and then measuring the level of the mRNA of the DDX19B gene or a protein thereof; And (b) selecting an antiviral agent for an influenza virus when the level of the mRNA or the protein of the gene is lower than that of a control sample not treated with the candidate substance .
According to a preferred embodiment of the present invention, the step of measuring the mRNA level of the DDX19B gene comprises the steps of RT-PCR, competitive RT-PCR, real-time reverse transcriptase polymerase Can be measured by real time quantitative RTPCR, RNase protection method, northern blotting or gene chip.
According to another preferred embodiment of the present invention, the step of measuring the mRNA level of the DDX19B gene may use a primer or a probe specifically binding to the DDX19B gene.
According to another preferred embodiment of the present invention, the step of measuring the level of the protein of the DDX19B gene may use an antibody that specifically binds to the protein
The present invention also provides a screening kit for antiviral agents against influenza virus comprising an agent for measuring the mRNA of the DDX19B gene or a protein level thereof.
According to a preferred embodiment of the present invention, the kit may be an RT-PCR kit, a competitive RT-PCR kit, a real-time RT-PCR kit, a DNA chip kit or a protein chip kit.
The present invention has revealed that the DDX19B gene acts as an important host factor for the replication of influenza virus. The present invention provides a pharmaceutical composition for preventing or treating an influenza virus infection using DDX19B gene of the present invention, a pharmaceutical composition for preventing or improving influenza virus infection A health functional food, a screening method of an antiviral agent against influenza virus, and a screening kit.
The DDX19B gene used as a new target in the present invention is a host factor that regulates viral replication during infection and has a distinctive feature that lacks the high mutation rate of the influenza virus gene that enables the development of resistance to drugs at present Therefore, it can be usefully used for the development of a novel antiviral agent which can replace the antiviral agents reported in the prior art.
1 is a photograph showing human lung epithelial A549 cells infected with the rPR8 NS1-GFP virus, and the arrows show cells infected with the rPR8 NS1-GFP virus.
FIG. 2 is a photograph showing image-based assay results using recombinant influenza A virus expressing GFP-tagged NS1A protein, showing negative control (scramble) and positive control (siCSE1L and siNXF1), respectively .
Figure 3 is a schematic diagram outlining a wide range of human genome-wide high throughput siRNA screening of whole human genomes.
FIG. 4 is a photograph of a cell infectious ability measured using the analysis program of the present invention, the upper line is a photograph obtained from a confocal microscope, and the lower line is a photograph analyzed using an image analysis program of the present invention.
5 shows the infectivity of cells transfected with siRNA against the DDX19B gene identified by the screening method of the present invention into scrambled siRNA-transformed cells (negative control,
FIG. 6 shows the results of the analysis of the H7 avian influenza virus (A / EM / Korea / W152 / 2006 (H7N7) and A / EM / Korea / W266 / 2007 (H7N4)), A / California / 07/2009 H1N1), A / Udorn / 307/72 (H3N2), and B / Florida / 04/2006, an influenza B type influenza virus.
Hereinafter, the present invention will be described in more detail.
As described above, there is an urgent need for new antiviral drugs for the prevention of influenza and pandemic influenza worldwide because of the widespread spread of antiviral drugs against influenza viruses.
Accordingly, it has been confirmed in the present invention that DDX19B gene is effective for prevention or treatment of influenza virus infection when DDX19B gene acts as an important host factor required for replication of influenza virus and inhibits its expression or activity, and DDX19B (DEAD box polypeptide 19B) gene expression suppressing agent, an inhibitor of DDX19B protein activity, or a mixture thereof as an active ingredient, thereby providing a pharmaceutical composition for the prevention or treatment of influenza virus infection. The DDX19B gene used as a novel target in the present invention is a host factor that regulates viral replication during infection and has a distinctive feature that lacks the high mutation rate of the influenza virus gene that enables the development of resistance to drugs at present, May be useful for the development of novel antiviral agents that can replace the reported antiviral agents.
The present invention provides a pharmaceutical composition for preventing or treating an influenza virus infection comprising an inhibitor of expression of DDX19B (DEAD box polypeptide 19B) gene, an inhibitor of DDX19B protein activity, or a mixture thereof as an active ingredient.
The pharmaceutical composition of the present invention is effective for the prevention or treatment of an influenza virus, preferably an influenza A virus infection. Examples of the influenza A virus include A / Puerto Rico / 8/34 (H1N1) A / EM / A / Udorn / 307/72 (H3N2), but there is a possibility that the DDX19B gene (H3N2) There is no particular limitation as long as the virus is a virus that inhibits expression or inhibits the activity of a protein to inhibit replication.
The term "DDX19B" is an abbreviation for " DEAD box polypeptide 19B ", and the DDX19B gene codes for a DEAD box protein exhibiting RNA-dependent ATPase and ATP-dependent RNA-annealing activity. The protein is assembled on the cytoplasmic fibrils of the nuclear complexes where this protein is involved in the delivery of mRNA from the nucleus. A number of alternatively spliced transcript variants have been found that encode different isoforms for this gene. However, the function of DDX19B in relation to influenza virus is unknown.
The DDX19B gene and protein sequence can be obtained from known databases such as NCBI. Specifically, the DDX19B gene sequence may be one disclosed in Gene Accession NM_001014449 of the NCBI database, and the DDX19B protein sequence may be one disclosed in the NCBI database NP_001014449.1, but is not limited thereto.
In the present invention, it was first confirmed that the DDX19B gene acts as an important host factor for influenza virus replication, and it was confirmed that influenza virus infection can be effectively treated by suppressing expression of the gene or protein activity.
In one embodiment of the present invention, recombinant influenza A virus (rPR8 NS1-GFP) expressing GFP-tagged NS1A protein (rPR8 NS1-GFP) was prepared (Fig. 1) and then subjected to an image-based assay Wide human genome-wide high throughput siRNA screening of whole human genetic material (Figure 3).
In order to compare the inhibitory effects of selected genes through siRNA high-speed screening (HTS), non-specific scrambled siRNAs (scrambles) were used as negative controls and human CSE1L (chromosome segregation 1-like), which has been identified as an important host factor controlling influenza, And siRNA targeting human NXF1 (nuclear RNA export factor 1) were used as positive controls to optimize image-based assays (FIG. 2).
The knockdown effect of each individual human gene was measured by calculating the infectivity (number of cells expressing GFP / number of total cells) using an in-house image analysis program (FIG. 4) The human gene DDX19B (SEQ ID NO: 1), which results in an inhibitory effect of over 50% on the replication of influenza A virus through comparison of Z-score analysis and positive control (siCSE1L, 0% infection rate) and negative control (Scramble, 100% infection rate) And the results are shown in FIG.
As shown in FIG. 5, the siRNA targeting the DDX19B gene of the present invention shows a remarkably superior infection inhibition rate than the siRNA targeting the ACP2, GRIN2C and DPF2 gene, which are conventionally known as host factors required for influenza virus infection Respectively. Thus, inhibiting the expression of the DDX19B gene of the present invention is considered to be more effective in treating influenza virus infection than inhibiting the expression of ACP2, GRIN2C and DPF2 genes.
Furthermore, as shown in Fig. 6, the siRNA targeting the DDX19B gene of the present invention is superior to the subtypes of influenza A virus including H7 avian influenza virus and the replication-inhibiting effect of influenza B virus, Prevention or treatment.
On the basis of the sequence of DDX19B, DDX19B expression inhibitor or activity inhibitor can be designed, and the sequence can be modified to some extent in this design. Those skilled in the art will appreciate that sequences that retain more than 80%, in particular more than 90%, more specifically more than 95%, and more particularly 98% Do.
As used herein, the term "DDX19B gene expression inhibitor" is used to refer to a substance that reduces the expression or activity of DDX19B. More specifically, the term " agent inhibiting DDX19B gene expression & . The substance inhibiting DDX19B expression can be used without limitation in the form of a compound, a nucleic acid, a peptide, a virus, or a vector containing the nucleic acid, which can inhibit DDX19B expression or activity by targeting DDX19B.
Specifically, the expression inhibitor of the DDX19B gene may be any one selected from the group consisting of antisense oligonucleotides, siRNA, shRNA and microRNA of the DDX19B gene.
The term "antisense oligonucleotide " in the present invention means DNA, RNA or derivatives thereof containing a nucleic acid sequence complementary to the sequence of a specific mRNA, and binds to a complementary sequence in the mRNA to inhibit translation of the mRNA into a protein .
The term "small interfering RNA (siRNA)" in the present invention means a nucleic acid molecule capable of mediating RNA interference or gene silencing. Since siRNA can inhibit the expression of a target gene, it is provided as an efficient gene knockdown method or as a gene therapy method.
Specifically, the siRNA may be any one selected from the group consisting of SEQ ID NOS: 1 to 4.
The term "short hairpin RNA (shRNA)" in the present invention refers to an oligodeoxynucleotide synthesizing oligonucleotide linking 3-10 base linkers between the sense of the siRNA sequence for the target gene and the complementary nonsense, (ShRNA) (short hairpin RNA), which is loop-shaped, is produced and converted into siRNA by intracellular Dicer to produce RNAi Effect. The shRNA shows a relatively long-term RNAi effect as compared to siRNA.
Such an expression inhibitor can be easily designed by those skilled in the art to induce the suppression of DDX19B gene expression according to techniques commonly used in the art.
In addition, the DDX19B protein activity inhibitor may be an antibody or an aptamer that specifically binds to a protein expressed from DDX19B gene, but is not limited thereto.
Such an antibody may be a polyclonal antibody, a monoclonal antibody or fragments of the antibody as long as the antibody has antigen binding ability. Furthermore, the antibody of the present invention includes a special antibody such as a humanized antibody, and a human antibody. In addition to the novel antibody, antibodies that are already known in the art may also be included. The antibody comprises a functional fragment of an antibody molecule as well as a complete form having the full length of two heavy chains and two light chains as long as the antibody has the property of binding specifically recognizing the protein expressed from the DDX19B gene. The functional fragment of the molecule of the antibody refers to a fragment having at least an antigen binding function, and includes, but is not limited to, Fab, F (ab ') 2, F (ab') 2 and Fv.
In the present invention, the term "Aptamer" is a single-stranded nucleic acid (DNA, RNA or modified nucleic acid) having a stable tertiary structure and capable of binding to a target molecule with high affinity and specificity. Aptamers are comparable to monoclonal antibodies due to their inherent high affinity (usually pM levels) and their ability to bind to target molecules with specificity, and there is a high likelihood of being an alternative antibody, especially as a "chemoantibody".
The term "prevention" as used in the present invention means all the actions of inhibiting or delaying the infection of influenza virus by administering the composition to an individual. The term "treatment" as used in the present invention means all the acts of administering the composition to influenza virus infected individuals so as to improve or improve the symptoms of infection.
The pharmaceutical composition of the present invention may be prepared using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the active ingredients, and examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Or a solubilizing agent such as a flavoring agent can be used. The pharmaceutical composition of the present invention may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the active ingredient for administration. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
The pharmaceutical preparation form of the pharmaceutical composition of the present invention may be in the form of granules, powders, coated tablets, tablets, capsules, suppositories, syrups, juices, suspensions, emulsions, drips or injectable solutions, . The pharmaceutical composition of the present invention may be administered orally or parenterally through intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, percutaneous, intranasal, inhalation, topical, rectal, ≪ / RTI > An effective amount of the active ingredient of the pharmaceutical composition of the present invention means an amount required for preventing or treating infection. Thus, the type of infection, the severity of the infection, the type and amount of active and other ingredients contained in the composition, the type of formulation and the age, body weight, general health status, sex and diet, time of administration, Rate of administration, duration of treatment, concurrent medication, and the like. For example, in the case of an adult, the inhibitor of the present invention may be used at a dose of 0.1 ng / kg to 10 g / kg when the active ingredient is a compound once or several times a day, 0.1 ng / kg to 10 g / kg for peptides, proteins or antibodies, and 0.01 ng / kg to 10 g / kg for antisense oligonucleotides, siRNA, shRNAi and miRNA.
The present invention also provides a health functional food for preventing or ameliorating an influenza virus infection comprising an inhibitor of expression of DDX19B (DEAD box polypeptide 19B) gene, an inhibitor of DDX19B protein activity, or a mixture thereof as an active ingredient.
The kind of the food is not particularly limited, and includes food in a conventional sense. Non-limiting examples of foods to which the material can be added include dairy products including meats, sausages, breads, chocolates, candies, snacks, confectionery, pizza, ramen noodles, other noodles, gums, ice creams, , A drink, an alcoholic beverage, and a vitamin complex.
When the health functional food of the present invention is a beverage composition, it may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Non-limiting examples of such natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Natural sweetening agents such as dextrin, cyclodextrin; Synthetic sweetening agents such as saccharin and aspartame, and the like. The proportion of the additional component added may be appropriately determined by a person skilled in the art.
In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the health functional food composition of the present invention may contain pulp for the production of natural fruit juice, fruit drink or vegetable drink. These components may be used independently or in combination of two or more. The ratios of these additives can also be suitably selected by those skilled in the art.
The present invention also provides a method for screening a DDX19B gene, comprising the steps of: (a) treating an antiviral candidate substance to a separated sample expressing the DDX19B gene, and then measuring the level of the mRNA of the DDX19B gene or a protein thereof; And (b) selecting an antiviral agent for an influenza virus when the level of the mRNA or the protein of the gene is lower than that of a control sample not treated with the candidate substance .
The level of DDX19B of the present invention is measured in a cell expressing the DDX19B gene in the absence of a candidate substance capable of preventing or treating an influenza virus infection and the level of the DDX19B of the present invention is measured in the presence of the candidate substance, A substance which reduces the expression level of DDX19B in the absence of the candidate substance in the absence of the candidate substance can be predicted as an antiviral agent for preventing or treating an influenza virus infection.
The step of measuring the level of the mRNA of the DDX19B gene or the protein thereof may be measured by a method of measuring the level of the DDX19B gene mRNA, and the agent may be a preparation used for determining the expression of DDX19B contained in the sample (RT-PCR), competitive RT-PCR, real-time RT-PCR, RNase protection assay (RPA), northern blotting a primer or a probe capable of specifically binding to a target gene used in a method such as blotting and gene chip analysis, but is not particularly limited thereto.
As used herein, the term "primer" refers to a nucleic acid sequence having a short free 3 'hydroxyl group, capable of forming a base pair with a complementary template, Refers to a short nucleic acid sequence that functions as a starting point. The primer can initiate DNA synthesis in the presence of reagents and four different nucleoside triphosphates for polymerization reactions (i.e., DNA polymerase or reverse transcriptase) at appropriate buffer solutions and temperatures.
As used herein, the term "probe" refers to a nucleic acid fragment such as RNA or DNA corresponding to a few nucleotides or hundreds of nucleotides, which can specifically bind to a gene or mRNA. An oligonucleotide, A probe, a single stranded DNA probe, a double stranded DNA probe, an RNA probe, or the like, and may be labeled for easier detection, but the present invention is not limited thereto.
The primers or probes of the present invention can be chemically synthesized using the phosphoramidite solid support method, or other well-known methods. Such nucleic acid sequences may also be modified using many means known in the art. Non-limiting examples of such modifications include, but are not limited to, methylation, capping, substitution of one or more natural nucleotides with one or more homologues, and modifications between nucleotides, such as uncharged linkers (e.g., methylphosphonate, phosphotriester, (E.g., phosphoramidate, carbamate, etc.) or charged linkages (e.g., phosphorothioate, phosphorodithioate, etc.). The nucleic acid can be in the form of one or more additional covalently linked residues such as a protein such as a nuclease, a toxin, an antibody, a signal peptide, a poly-L-lysine, an intercalator such as acridine, ), Chelating agents (e.g., metals, radioactive metals, iron, oxidizing metals, etc.), and alkylating agents. The nucleic acid sequences of the present invention can also be modified using labels that can directly or indirectly provide a detectable signal. Examples of labels include radioactive isotopes, fluorescent molecules, biotin, and the like.
The term " step of measuring the level of protein " used in the present invention is a process for confirming the presence and the expression level of the protein expressed from the DDX19B gene, specifically, an antibody that specifically binds to the protein of the gene Can be used to confirm the amount of protein.
In the present invention, "antibody" means a specific protein molecule directed against an antigenic site. For purposes of the present invention, an antibody refers to an antibody that specifically binds to a protein produced by expression of the DDX19B gene, and includes both polyclonal antibodies, monoclonal antibodies, and recombinant antibodies. The generation of an antibody that specifically binds to DDX19B protein can be easily produced using techniques well known in the art.
Polyclonal antibodies can be produced by methods well known in the art for obtaining DDX19B protein antigen into animals and blood from animals to obtain sera containing antibodies. Such polyclonal antibodies can be prepared from any animal species host, such as goats, rabbits, sheep, monkeys, horses, pigs, small dogs, and the like.
Monoclonal antibodies can be obtained from the hybridoma method (see Kohler and Milstein (1976) European Jounal of Immunology 6: 511-519), or the phage antibody library (Clackson et al, Nature, 352: 1992, Marks et al., J. Mol. Biol., 222: 58, 1-597, 1991). The antibody prepared by the above method can be separated and purified by gel electrophoresis, dialysis, salt precipitation, ion exchange chromatography, affinity chromatography, and the like.
The antibodies of the present invention also include functional fragments of antibody molecules as well as complete forms with two full-length light chains and two full-length heavy chains. A functional fragment of an antibody molecule refers to a fragment having at least an antigen binding function, and includes Fab, F (ab ') 2, F (ab') 2 and Fv.
Methods for assaying the amount of the target protein bound to the antibody using the antibody include Western blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Immunoprecipitation Assay, Complement Fixation Assay, Fluorescence Activated Cell Sorter (FACS), Protein Chip Protein (FACS), Immunoprecipitation Assay, Immunoprecipitation Assay, Ouchterlony Immunoprecipitation, Rocket Immunoelectrophoresis, chip, but are not limited thereto.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
Cell culture
Human lung epithelial A549 cells used in the present invention were purchased from the American Type Culture Collection (ATCC, Catalog No. CCL-185 TM ), and cultured in Dulbecco's Modified Eagle Medium - high glucose (DMEM-HG) supplemented with 10% fetal bovine serum FBS) and 1% penicillin & streptomycin.
Preparation of Recombinant Influenza A Virus Expressing Green Fluorescent Protein
Recombinant influenza A virus (A / Puerto Rico / 8/34) expressing the green fluorescent protein used in the present invention can be obtained from Adolfo Garcia-Sastre (Professor, Department of Microbiology and Director of the Global Health & Emerging Pathogens Institute at Mount Sinai School of Medicine in New York), and the approximate manufacturing method is as follows. The open reading frame (ORF) of the NS1 gene encoding the nonstructural protein 1 (NS1 protein) of the influenza gene is fused with the GFP gene encoding the green fluorescent protein to generate the NS-GFP gene fragment . This gene fragment is inserted into a DNA plasmid that can be expressed in cells. The DNA plasmid containing the NS-GFP gene fragment was transfected with each of seven plasmids containing seven genes (influenza viruses other than NS gene) (PB2, PB1, PA, HA, NP, Into the cell via the method. Within the cell, these plasmids produce recombinant influenza virus through reverse genetics based technology.
rPR8 NS1- GFP Image based essay using virus
Human lung epithelial A549 cells were infected with the rPR8 NS1-GFP virus of Example 1 for 10 hours. Cells were fixed and cell nuclei were stained. The infected cells were imaged on a confocal fluorescence imaging system (Evotec Technologies High-Throughput Cell Analyzer Opera, Perkin Elmer, USA) at 20x magnification and analyzed with an in-house image mining (IM) platform.
As shown in Fig. 1, NS1-GFP and nuclei were visualized in green and red, respectively, and the arrows indicate rPR8 NS1-GFP virus infected cells.
In the present invention, a non-specific scramble siRNA (Scramble, Dharmacon) was used as a negative control to compare the inhibitory effect of the selected gene through the high-speed screening of siRNA (HTS), and the human CSE1L (Dharmacon) targeting segregation 1-like and human nuclear export factor 1 (NXF1) as a positive control to optimize image-based assays.
Cells were then fixed and stained after infection with the rPR8 NS1-GFP virus as described above, imaged on a 20X magnification confocal fluorescence imaging system and analyzed with an internal IM platform. As a result, knockdown of CSE1L and NXF1 as shown in Fig. 2 effectively blocked the expression of GFP-tagged virus NS1A protein.
Wide range of human genome siRNA Screening
RNA interference (RNAi) technology is a powerful tool for understanding host pathogen relationships. In this example, extensive siRNA high-speed screening (HTS) of the genome was used as shown in the schematic diagram of FIG. 3 to identify host factors required for replication of influenza virus in human cells.
For the reading on HTS, recombinant influenza A virus (rPR8 NS1-GFP) of Example 1 above was used and 18,055 indicated genes in human lung epithelial A549 cells (Dharmacon, # GU-105005, Human ON-TARGETplus siRNA Library - Whole Genome) of an entire human genome consisting of approximately 72,000 siRNA targeting siRNA pools
Add 10 μl of siRNA to a 384-well plate and dispense 5 μl of the solution containing the transfection reagent into each well. After standing at room temperature for 20 minutes, 30 μl of A549 cells are dispensed into 384-well plates. After 48 hours, the transfected A549 cells are infected with rPR8 NS1-GFP virus for 10 hours. A549 cells transfected with individual siRNAs are fixed with paraformaldehyde and stained with Hoechst 33342 (Thermo Fiusher Scientific), a nuclear dyeing reagent. 48 hours before infection with the rPR8 NS1-GFP virus, A549 cells transfected with individual siRNAs were fixed and stained 10 hours after infection to monitor viral infectivity.
The knockdown effect of each individual human gene was determined by calculating the infectivity (number of cells expressing GFP / number of total cells) using an in-house image analysis program (FIG. 4).
A genomic human gene that causes more than 50% inhibition of replication of influenza A virus through a strong Z-score analysis and comparison of positive control (siCSE1L, 0% infection rate) and negative control (Scramble, 100% infection rate) The gene was identified, and the result is as shown in Fig.
In FIG. 5, ACP2, GRIN2C and DPF2 are genes known to be host factors necessary for influenza virus infection (Shapira SD et al., (2009) A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463: 818-822; and Hao L et al., (2008) Drosophila RNAi screen Nature 454: 890-893), siRNAs targeting these genes and the siRNAs targeting the DDX19B gene of the present invention were compared against influenza A virus infection inhibitory effects.
As a result, as shown in FIG. 5, it was confirmed that siRNA targeting the DDX19B gene of the present invention exhibited remarkably superior infection inhibition rate than siRNA targeting ACP2, GRIN2C and DPF2. Therefore, inhibiting the expression of the DDX19B gene of the present invention is considered to be more effective for treating influenza virus infection than suppressing the expression of ACP2, GRIN2C and DPF2 genes.
The sequences of siRNA targeting DDX19B, ACP2, GRIN2C and DPF2 used in this Example are shown in Table 1 below.
A subtype of influenza A virus or influenza B type influenza A Suppress replication against viruses effect
In this example, the expression of the gene was inhibited by the siRNA targeting the DDX19B gene to determine whether it exhibited inhibitory effects on other subtype or influenza B virus replication in addition to rPR8 NS1-GFP, the type A influenza virus used for screening (A / EM / Korea / W152 / 2006, H7N7 and A / EM / Korea / W266 / 2007, H7N4), A / California / 07/2009 (H1N1) and H5N1 influenza virus subtypes A / Udorn / 307/72 (H3N2), and the influenza B virus, B / Florida / 04/2006.
The degree of infection with the viruses was imaged through immunofluorescence assay using an antibody that specifically binds to the viral protein nucleoprotein (NP). Sensitivity (number of cells expressing NP / number of total cells) was measured using an internal image analysis program. The measured infectious capacity was normalized by a negative control (scramble, 100% infection rate) and displayed as a bar graph.
As a result, as shown in FIG. 6, the DDX19B gene expression inhibition effected the replication inhibition of the H7N7, H7N4 and H3N2 subtypes of influenza A virus by more than 50%. Another H1N1 subtype virus A / California / 07 / 2009 cloning also caused more than 80% inhibition. In addition, replication of the B virus was inhibited by about 70% due to the knockdown of the DDX19B gene. Therefore, it was confirmed that DDX19B gene expression inhibition was superior to the subtypes of influenza A virus including H7 avian influenza virus and the replication inhibition of influenza B virus, thereby effectively preventing or treating infection by these viruses.
<110> Institut Pasteur Korea <120> Novel human gene crucial for the replication of influenza virus and use thereof <130> 1060764 <160> 16 <170> Kopatentin 2.0 <210> 1 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> DDX19B siRNA <400> 1 gaacaagugu cugucguca 19 <210> 2 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> DDX19B siRNA <400> 2 agaccuaccu gcaccggau 19 <210> 3 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> DDX19B siRNA <400> 3 cugcagugau ugagcgcuu 19 <210> 4 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> DDX19B siRNA <400> 4 uuaucaaacu gaagcguga 19 <210> 5 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> ACP2 siRNA <400> 5 gcacgacacu acccugguu 19 <210> 6 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> ACP2 siRNA <400> 6 uaucacggcu uccuaaaca 19 <210> 7 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> ACP2 siRNA <400> 7 ggacuuccuu cgccucaca 19 <210> 8 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> ACP2 siRNA <400> 8 gcaagagguu uaugugcga 19 <210> 9 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> GRIN2C siRNA <400> 9 gagcauggcg uccuauaca 19 <210> 10 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> GRIN2C siRNA <400> 10 ucagaagugu gaguuauca 19 <210> 11 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> GRIN2C siRNA <400> 11 cgcaguaacu accgugaca 19 <210> 12 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> GRIN2C siRNA <400> 12 caagagcaau acaucgaca 19 <210> 13 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> DPF2 siRNA <400> 13 gaccaacagu cgagcgcga 19 <210> 14 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> DPF2 siRNA <400> 14 gaagauacuc ccaagcguc 19 <210> 15 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> DPF2 siRNA <400> 15 ccggacagcu guacuccua 19 <210> 16 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> DPF2 siRNA <400> 16 ggaguagccc agagcaauu 19
Claims (13)
(b) A / Puerto Rico / 8/34 (H1N1), A / EM / Korea / W152 / 2006 when the mRNA of the gene or the protein level thereof is lower than the level of the control sample not treated with the candidate substance H7N7), A / EM / Korea / W266 / 2007 (H7N4), A / California / 07/2009 (H1N1), A / Udorn / 307/72 (H3N2) And selecting as an antiviral agent against any one or more influenza viruses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160077941A KR101723435B1 (en) | 2016-06-22 | 2016-06-22 | Novel human gene crucial for the replication of influenza virus and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160077941A KR101723435B1 (en) | 2016-06-22 | 2016-06-22 | Novel human gene crucial for the replication of influenza virus and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101723435B1 true KR101723435B1 (en) | 2017-04-05 |
Family
ID=58586726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160077941A KR101723435B1 (en) | 2016-06-22 | 2016-06-22 | Novel human gene crucial for the replication of influenza virus and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101723435B1 (en) |
-
2016
- 2016-06-22 KR KR1020160077941A patent/KR101723435B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| Sandie Munier et al., Molecular & Cellular Proteomics 12(10), pages 2845-2855 (2013.07.01)* |
| Sandie Munier et al., Molecular & Cellular Proteomics 12(10), pages 2845-2855 (2013.07.01)* * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ling et al. | Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I | |
| US20100021489A1 (en) | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection | |
| US9260755B2 (en) | Compositions and methods for characterizing and treating muscular dystrophy | |
| EP3336548B1 (en) | Method for providing information on chronic myeloid leukemia | |
| US11905330B1 (en) | Methods for weight reduction | |
| TWI816712B (en) | Screening reagent for active ingredient of cancer promoting factor expression inhibitor and screening method thereof, screening reagent for active ingredient of cancer preventive or therapeutic agent and screening method thereof, cancer promoting factor expression inhibitor, and cancer preventive or therapeutic agent | |
| AU2014296288A1 (en) | Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules | |
| Duarte et al. | Age-dependent effects of the recombinant spike protein/SARS-CoV-2 on the M–CSF–and IL-34-differentiated macrophages in vitro | |
| JP7175526B2 (en) | Preventive/therapeutic agents for diseases related to cell migration regulation and disease activity assessment/prognostic evaluation for pulmonary interstitial diseases | |
| KR101693243B1 (en) | Novel human gene crucial for the replication of influenza virus and use thereof | |
| JP7177439B2 (en) | Pro-inflammatory factor expression inhibitor, screening method for active ingredient thereof, expression cassette useful for said method, diagnostic agent, and diagnostic method | |
| KR101723435B1 (en) | Novel human gene crucial for the replication of influenza virus and use thereof | |
| KR101712856B1 (en) | Novel human gene crucial for the replication of influenza virus and use thereof | |
| KR101723434B1 (en) | Novel human gene crucial for the replication of influenza virus and use thereof | |
| Zhao et al. | Avian influenza viruses suppress innate immunity by inducing trans-transcriptional readthrough via SSU72 | |
| US10849906B2 (en) | Use of Akt2 in diagnosis and treatment of tumor | |
| US20180259502A1 (en) | A Pharmaceutical composition for treating or preventing obesity | |
| JP2011502108A (en) | Cancer preventive / therapeutic agent | |
| JP6839707B2 (en) | Prevention, diagnosis and treatment of cancers that overexpress GPR160 | |
| CN110215518B (en) | Application of PinX1 and target molecule thereof in preparation of medicine for treating kidney cancer | |
| JP6226315B2 (en) | Inflammatory disease preventive / therapeutic agent and screening method for inflammatory disease prophylactic / therapeutic agent | |
| WO2022085687A1 (en) | Prophylactic or therapeutic agent for respiratory disease, examination method, examination reagent, method for screening active ingredient of prophylactic or therapeutic agent, and method for evaluating induction or exacerbation | |
| KR101385783B1 (en) | Deleted in breast cancer-1 as a marker for the diagnosis of hepatocellular carcinomas and as a therapeutic agent thereof | |
| JP2019158753A (en) | Biomarkers for lymphangioleiomyomatosis | |
| US20220288087A1 (en) | Pim1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |